Melphalan, antimelanoma immunity, and inflammation-letterr

Cancer Research

Volumn 75, Issue 24, 2015, Pages 5398-5399

  martner, Anna ^a   Johansson, Junko ^a   Ben Shabat, Ilan ^b   Bagge, Roger Olofsson ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; MELPHALAN; ALKYLATING AGENT; CALRETICULIN; MEMBRANE ANTIGEN;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; CD8+ T LYMPHOCYTE; CELL DEATH; CELL VIABILITY; DRUG EFFICACY; HUMAN; LETTER; LIMB PERFUSION; LYMPHOCYTE ACTIVATION; MELANOMA METASTASIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; MELANOMA; PHYSIOLOGY; SKIN TUMOR;

ANIMALS; ANTIGENS, SURFACE; ANTINEOPLASTIC AGENTS, ALKYLATING; CALRETICULIN; HUMANS; MELANOMA; MELPHALAN; SKIN NEOPLASMS;

EID: 84955486821     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-1184     Document Type: Letter

References (2)

1. Dudek-Peric AM, Ferreira GB, Muchowicz A, Wouters J, Prada N, Martin S, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res 2015;75: 1603-14.
2. Olofsson R, Lindberg E, Karlsson-Parra A, Lindner P, Mattsson J, Andersson B. Melan - A specific CD8+ T lymphocytes after hyperthermic isolated limb perfusion: a pilot study in patients with in-transit metastases of malignant melanoma. Int J Hyperthermia 2013;29:234-8.